The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Clinical trials == Clinical and experimental studies on gastropod inspired adhesives report results across a range of applications such as skin treatment and wound healing. In one human study using Cornu aspersum slime, 27 participants were divided into four groups based on age and gender. The Cornu Aspersum Muller slime and a commercial slime were applied to opposite sides of the face once daily for 15 days. Female participants applied the slime at the corners of their eyes, while male participants applied it to the forehead. The results indicated that some women experienced increased skin firmness when using Cornu aspersum, with more noticeable effects in participants under forty years old compared to those above that age. For male participants, the results were less statistically significant overall. This was also supported by subcutaneous implantation and myocardium attachment studies in rats. One finding was that the gastropod-inspired adhesive produced a lower inflammatory response compared to some existing adhesive methods under the tested conditions. Overall, these findings highlight observed differences between gastropod inspired adhesives and traditional wound dressings and adhesives, which have been reported to exhibit reduced adhesion in wet conditions.
==== Anti-viral ==== In 2021, SLR14 was reported to prevent infection in the lower respiratory tract and severe disease in an interferon type I (IFN-I)–dependent manner in mice. Immunodeficient mice with chronic SARS-CoV-2 infection experienced near-sterilizing innate immunity with no help from the adaptive immune system.
About 86% of molybdenum produced is used in metallurgy, with the rest used in chemical applications. The estimated global use is structural steel 35%, stainless steel 25%, chemicals 14%, tool & high-speed steels 9%, cast iron 6%, molybdenum elemental metal 6%, and superalloys 5%. Molybdenum can withstand extreme temperatures without significantly expanding or softening, making it useful in environments of intense heat, including military armor, aircraft parts, electrical contacts, industrial motors, and supports for filaments in light bulbs. Most high-strength steel alloys (for example, 41xx steels) contain 0.25% to 8% molybdenum. Even in these small portions, more than 43,000 tonnes of molybdenum are used each year in stainless steels, tool steels, cast irons, and high-temperature superalloys. Molybdenum is also used in steel alloys for its high corrosion resistance and weldability. Molybdenum contributes corrosion resistance to type-300 stainless steels (specifically type-316) and especially so in the so-called superaustenitic stainless steels (such as alloy AL-6XN, 254SMO and 1925hMo). Molybdenum increases lattice strain, thus increasing the energy required to dissolve iron atoms from the surface. Molybdenum is also used to enhance the corrosion resistance of ferritic (for example grade 444) and martensitic (for example 1.4122 and 1.4418) stainless steels. Because of its lower density and more stable price, molybdenum is sometimes used in place of tungsten.
A Scanner Darkly is a science fiction novel by American writer Philip K. Dick, published in 1977. The semi-autobiographical story is set in a dystopian Orange County, California, in the then-future of June 1994, and includes an extensive portrayal of drug culture and drug use (both recreational and abusive). The novel is one of Dick's best-known works and served as the basis for a 2006 film of the same name, directed by Richard Linklater.
An abnormally low hemoglobin, hematocrit, or red blood cell count indicates anemia. Anemia is not a diagnosis on its own, but it points to an underlying condition affecting the person's red blood cells. General causes of anemia include blood loss, production of defective red blood cells (ineffective erythropoeisis), decreased production of red blood cells (insufficient erythropoeisis), and increased destruction of red blood cells (hemolytic anemia). Anemia reduces the blood's ability to carry oxygen, causing symptoms like tiredness and shortness of breath. If the hemoglobin level falls below thresholds based on the person's clinical condition, a blood transfusion may be necessary. An increased number of red blood cells, leading to an increase in the hemoglobin and hematocrit, is called polycythemia. Dehydration or use of diuretics can cause a "relative" polycythemia by decreasing the amount of plasma compared to red cells. A true increase in the number of red blood cells, called absolute polycythemia, can occur when the body produces more red blood cells to compensate for chronically low oxygen levels in conditions like lung or heart disease, or when a person has abnormally high levels of erythropoietin, a hormone that stimulates production of red blood cells. In polycythemia vera, the bone marrow produces red cells and other blood cells at an excessively high rate. Evaluation of red blood cell indices is helpful in determining the cause of anemia. If the MCV is low, the anemia is termed microcytic, while anemia with a high MCV is called macrocytic anemia.
Sources: en.wikipedia.org
== Green chemistry == Chemical synthesis using green chemistry promotes the design of new synthetic methods and apparatus that simplify operations and seeks environmentally benign solvents. Key principles include atom economy, which aims to incorporate all reactant atoms into the final product, and the reduction of waste and inefficiencies in chemical processes. Innovations in green chemistry, contribute to more sustainable and efficient chemical synthesis, reducing the environmental and health impacts of traditional methods.
Fibrillogenesis is the development of fine fibrils normally present in collagen fibers of connective tissue. It is derived from the New Latin fibrilla (meaning fibrils, or pertaining to fibrils) and Greek genesis (to create, the process by which something is created). The assembly of collagen fibrils, fibrillogenesis appears to be a self-assembly process although there is much speculation about the specifics of the mechanism through which the body produces collagen fibrils. In the body, collagen fibrils are composed of several types of collagen as well as macromolecules. Type I collagen is the most abundant structural macromolecule within the vertebrate body and also represents the most abundant collagen found within various collagen fibrils There are immense differences in the types of collagen fibrils that exist within the body. For instance, fibrils within the tendon vary in width and are banded into aggregates that form fibril bundles that resist forces of tension within one dimension. Similarly, fibrils that form the translucent corneal stromal matrix form orthogonal sheets and withstand the force of traction in two dimensions. These two structurally different collagen fibrils are speculated to be formed from the same molecules with type I collagen being the primary collagen found within both structures.
== Clinical significance == A common pathological disorder concerning the tunica externa is scurvy, also known as vitamin C deficiency. Scurvy occurs because vitamin C is essential for the synthesis of collagen, and without it, the faulty collagen cannot maintain the vein walls and rupture, leading to a multitude of problems.
Krypton's multiple emission lines make ionized krypton gas discharges appear whitish, which in turn makes krypton-based bulbs useful in photography as a white light source. Krypton is used in some photographic flashes for high speed photography. Krypton gas is also combined with mercury to make luminous signs that glow with a bright greenish-blue light. Krypton is mixed with argon in energy efficient fluorescent lamps, reducing the power consumption, but also reducing the light output and raising the cost. Krypton costs about 100 times as much as argon. Krypton (along with xenon) is also used to fill incandescent lamps to reduce filament evaporation and allow higher operating temperatures. Krypton's white discharge is sometimes used as an artistic effect in gas discharge "neon" tubes. Krypton produces much higher light power than neon in the red spectral line region, and for this reason, red lasers for high-power laser light-shows are often krypton lasers with mirrors that select the red spectral line for laser amplification and emission, rather than the more familiar helium-neon variety, which could not achieve the same multi-watt outputs. The krypton fluoride laser is important in nuclear fusion energy research in confinement experiments. The laser has high beam uniformity, short wavelength, and the spot size can be varied to track an imploding pellet. In experimental particle physics, liquid krypton is used to construct quasi-homogeneous electromagnetic calorimeters.
== External links == Biological Products at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Debbie Strickland (2007). "Guide to Biotechnology" (PDF). Biotechnology Industry Organization (BIO). Archived from the original (PDF) on 2007-09-27. Retrieved 2007-12-17. Timothy B. Coan; Ron Ellis (2001-06-01). "Report for USA Specialty Pharmaceuticals: Generic Biologics: The Next Frontier" (PDF). Consumer Project on Technology. Retrieved 2007-12-17. "About biologics". National Psoriasis Foundation. 2006-11-01. Archived from the original on 2006-01-01. Retrieved 2007-12-17.
Sources: en.wikipedia.org
(2026) interpret the morphological variation of Middle Stone Age human mandibles from the Klasies River Main Site (South Africa) as not conclusively indicative of presence of more than one population lineage. García-Morato et al. (2026) reconstruct climate and vegetation changes in southern Africa from Marine Isotope Stage 5 to Marine Isotope Stage 3, and find that the emergence of the 76,000-67,000-years-old Stilbaai lithic technocomplex coincided with humid, cool phase that likely supported high biomass and expanded habitable zones, while the 64,000-60,000 years of Howiesons Poort technocomplex arose and ended during peaks of aridity, with a wetter interval midway through them. Evidence from the study of engraved ostrich eggshell fragments from the Howiesons Poort technocomplex, indicating that the studied engravings represent an expression of complex graphic representation by Middle Stone Age humans, is presented by Decembrini et al. (2026). Alichane et al. (2026) study the morphology of the enamel-dentine junction of the first and second molars in hominins associated with the Middle Stone Age Aterian technocomplexes in northwestern Africa, reporting evidence of overall closer morphological similarity to anatomically modern humans than to Neanderthals, but also evidence of morphological differences that might be related to the age and large size of the studied teeth.
The greater sac, represented in red in the diagrams above. The lesser sac, represented in blue. The lesser sac is divided into two "omenta": The lesser omentum (or hepatogastric) is attached to the lesser curvature of the stomach and the liver. The greater omentum (or gastrocolic) hangs from the greater curvature of the stomach and loops down in front of the intestines before curving back upwards to attach to the transverse colon. In effect it is draped in front of the intestines like an apron and may serve as an insulating or protective layer. The mesentery is the part of the peritoneum through which most abdominal organs are attached to the abdominal wall and supplied with blood and lymph vessels and nerves.
== Reception == The "Techno-Optimist Manifesto", a 2023 essay by Marc Andreessen, has been described by the Financial Times and the German Süddeutsche Zeitung as espousing the views of effective accelerationism. Mother Jones also characterized it as expressing effective accelerationism and reported that Andressen cited Land's work. David Swan of The Sydney Morning Herald has criticized effective accelerationism due to its opposition to government and industry self-regulation. He argues that "innovations like AI needs thoughtful regulations and guardrails ... to avoid the myriad mistakes Silicon Valley has already made." During the 2023 Reagan National Defense Forum, U.S. Secretary of Commerce Gina Raimondo cautioned against embracing the "move fast and break things" mentality associated with "effective acceleration [sic]". She emphasized the need to exercise caution in dealing with AI, stating "that's too dangerous. You can't break things when you are talking about AI." In a similar vein, Ellen Huet argued on Bloomberg News that some of the ideas of the movement were "deeply unsettling", focusing especially on Guillaume Verdon's "post-humanism" and the view that "natural selection could lead AI to replace us as the dominant species."
== Founding of Novo Terapeutisk Laboratorium == In 1924 a dispute occurred at Nordisk: Thorvald was fired by Hans Christian Hagedorn, co-founder of Nordisk, and Harald resigned in solidarity. In February 1925 the brothers formally founded Novo Terapeutisk Laboratorium. The company developed a dedicated insulin production facility and a specialty injection device (the "Novo Syringe").
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.